With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.16011-97-5,N1,N4-Dimethylbutane-1,4-diamine,as a common compound, the synthetic route is as follows.
A mixture of 2-chloro-3-nitropyridin-4-amine (LXXXIII) (1.0 g, 5.76 mmol) and DIPEA (1.0 mL, 5.76 mmol) in THF (20 mL) was stirred at room temperature for 1 h. The reaction was concentrated to dryness and the residue was taken up in EtOAc and the organic layer was washed with 2 x water then 1 x brine solution. The organic layers were then separated and dried (MgSO4) before concentration to dryness to obtain N2-methyl-N2-(4- (methylamino)butyl)-3-nitropyridine-2,4-diamine (LXXXIV) (160 mg, 6.32 mmol, 109.6% yield) as dark brown gum which was used for next step without purification. ESIMS found for C11H19N5O2 m/z 254.1 (M+H).
16011-97-5, The synthetic route of 16011-97-5 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; SAMUMED, LLC; KC, Sunil Kumar; MITTAPALLI, Gopi Kumar; CHIRUTA, Chandramouli; HOFILENA, Brian Joseph; (128 pag.)WO2019/241540; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI